Hester Biosciences Ltd (BSE: 524669) is a Mehsana, Gujarat-based company in the Biological Products industry. With a market capitalisation of ₹1,905 Cr, it ranks #1,264 by market cap among the 6,137 Indian listed companies on FinBizNet, and #2 of 5 in Biological Products. At ₹2,056.60 (as of 25 Oct 2026), the share price is 23.4% below its 52-week high of ₹2,683.60 and 65.9% above its 52-week low of ₹1,239.30. The share price is up 19.5% over one year and down 13.1% over three months.
| Current Price | ₹2,056.60 |
|---|---|
| Market Cap | ₹1,905 Cr |
| BSE Code | 524669 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Biological Products |
| P/E Ratio | 34.5 |
| Return on Equity | 16.55% |
| Return on Assets | 6.51% |
| 52-Week Range | ₹1,239.30 – ₹2,683.60 |
| 1-Year Price Change | +19.5% |
| 3-Month Price Change | -13.1% |
| Beta (1Y) | -0.11 |
| Dividend Yield | 0.49% |
| Headquarters | Mehsana, Gujarat |
| Website | www.hester.in |
| Revenue | ₹77 Cr |
|---|---|
| Net Profit | ₹95 Cr |
| Net Margin | 122.6% |
| EPS (Basic) | ₹113.71 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek’s disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella abortus, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming aids,
1. Poultry Healthcare-This segment engages in manufacturing poultry vaccines; and trading of poultry. 2. Animal Healthcare-This segment engages in manufacturing of large animal vaccines; and trading of large animal health products. 3. Unallocated Assets-0 4. Segment Adjustment-0
1. Poultry Healthcare-61.9% 2. Animal Healthcare-38.1%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Biocon Limited | ₹56,860 Cr | 120.9 | 1.15% | ₹4,336 Cr | -9.7% |
| Hester Biosciences Ltd | ₹1,905 Cr | 34.5 | 16.55% | ₹77 Cr | +19.5% |
| Zenotech Laboratories Ltd | ₹263 Cr | -238.3 | -1.12% | — | -20.3% |
| Transgene Biotek Ltd. | ₹19 Cr | -11.5 | -17.96% | ₹0 Cr | -39.2% |
| Hindustan Bio Sciences Ltd | ₹7 Cr | -86.3 | -9.12% | — | -18.7% |
Listed by market capitalisation. Ratios are shown for context only.
Hester Biosciences Ltd is trading at ₹2,056.60, with a market capitalisation of ₹1,905 Cr.
Hester Biosciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Biological Products).
Hester Biosciences Ltd has a P/E of 34.5 and a return on equity of 16.55%.
Hester Biosciences Ltd is listed on the BSE under the scrip code 524669.
Hester Biosciences Ltd's share price is up 19.5% over one year and down 13.1% over three months. Its 52-week range is ₹1,239.30 to ₹2,683.60.
In Q1 FY27, Hester Biosciences Ltd reported revenue of ₹77 Cr and net profit of ₹95 Cr, with basic EPS of ₹113.71 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.